Dermapharm Holding Se

Dermapharm’s portfolio of pharmaceuticals, medical devices and food supplements are tailored to selected therapeutic areas in which the Company is a market leader, especially in Germany. Provided fintech advice to PayPoint, which is a leading fintech business specialising in payment transfers to enable bill payments through a network of local stores. Advised AIM-listed Equals Group plc on the acquisition of the business and assets of Effective FX Limited, an international payments specialist.

Advising Verifone on a range of payments regulation and operational issues across its European footprint. Advising Uncapped, Student Finance, Hokodo, Lenkie on embedded finance and banking as a service ecosystem. Advised PrimaryBid, an FCA-regulated platform that connects retail investors with listed companies on equity offerings, on its Series B fundraising round to raise approximately $50m.

White & Case Llp

On the emerging technology side, the practice handles transactional work, disputes and regulatory matters. Mark Prinsleyleads the IP and IT group and also the outsourcing practice; he has considerable experience of conducting outsourcing projects for large financial institutions. Oliver Yaros is recommended for digital transformation projects and IP transactions.

Community portal – Bulletin board, projects, resources and activities covering a wide range of Wikipedia areas. The online courses cover regulatory topics and specialist subject areas (such as drug safety, various product-specific training courses). Euromed also focuses on exploiting the full potential of the plants used, for instance its product “Lipidic Sterolic Saw Palmetto Extract” which as the name suggests is sourced from saw palmetto. This ensures that they have an optimal fatty acid content and means that the raw material is fully traceable. The residue remaining after fruit extraction is used for recycling products such as natural dyes.

Advised global, independent, InsurTech-focused venture capital fund Eos Venture Partners on its investment in InsurTech company Concirrus as part of a $26m extended Series B round, led by Albion VC and CommerzVentures. Assisted Kreos Capital Partners with several matters, including fintech financing and equity subscription. Advised Nucleus Financial Group PLC, an AIM-quoted fintech provider of platform services to IFAs on a £145m bid for the company.

In 2002, he was head of the supply center at Schering Aktiengesellschaft, Berlin. Advised Neptune Networks on its fundraise of up to £14.95m of new equity in Neptune Networks Limited offered to existing bank shareholders of Neptune via a two tranche investment. Advised fast-growing fintech company Pollinate on its series C round and global expansion.

Biocon And Viatris

Squire Patton Boggs’ work for clients in the fintech sector covers corporate and finance transactions, as well as a wide ambit of regulatory issues. Robert Bray, who heads up the team, is experienced in including private equity and venture capital work. In a recent development, limefx Julian Thatcherjoined from an in-house role at MHMK Capital. White & Case LLPis able to cover all the legal, regulatory and commercial issues facing its clients, which is underpinned by its strengths across a multitude of disciplines, as well as its international reach.

  • Fintech-related corporate and finance transactions are among the drivers of activity, as are regulatory matters, IP, cybersecurity and dispute resolution.
  • The integrated reporting within the system means that those responsible for specific topics always have an overview of how effective their mandatory training programmes are and can further optimise them where necessary.
  • Rae is recommended for corporate transactions, while Pantlin handles blockchain, procurement and systems implementation matters.

In autumn 2020, we launched another new construction project at subsidiary axicorp, with a stateof-the-art production, storage and administration building set to replace the former leased premises. As well as meeting the energy standards currently in force in 2020, three-quarters of the roofing space is designed as an extensive green roof. Energy demand will be reduced by an air-to-water heat pump and a condensing gas boiler. Fresh water consumption will also be reduced by using rainwater from the roof to flush the toilets.

Osborne Clarke Llp

In addition to his position at Dermapharm, Dr Kern was and is active in various companies and associations in the stone and earth industry that are not listed on the stock exchange. She joined the company in 1991 and has been responsible for business development, international affairs, regulatory affairs and pharmacovigilance ever since. Prior to joining Dermapharm she worked for the pharmaceutical company Dorsch GmbH and the seal producer Feodor Burgmann GmbH & Co. In the “Branded pharmaceuticals and other healthcare products” segment, Dermapharm has approximately 1,300 marketing authorisations with more than 380 active pharmaceutical ingredients.

The Company’s integrated business model comprises in-house development, production and the distribution of brand products by a trained pharmaceutical sales force. In addition to its main location in Brehna near Leipzig, Dermapharm also operates other production, development and distribution locations in Europe and the United States. Advising Multi Service Technology Solutions, Inc doing business as TreviPay as lead global regulatory counsel on the payments regulatory aspects of a deal which saw MSTS sold to private equity firm, Corsair Capital. Dermapharm is firmly committed to continuing on this profitable growth course in the future. Advised Deutsche Bank AG on a strategic, multi-year partnership with Google Cloud aimed at accelerating the bank’s transition to cloud services and the co-innovation of new products and services.

Fox Williams Llp

Regulatory and dispute resolution work is another mainstay of the work undertaken by the firm, which acts for clients such as start-ups and growth businesses, challenger banks and large mainstream financial institutions. It has particular Venture fund experience of structural, strategic and commercial transformations, and digitisation. With former practice head Kate Johnson leaving the practice in April 2020, the team is now jointly led by Nikki Worden and Mark Wesker.

Pinsent Masons LLP is particularly strong in payments and digital identification matters. It also advises fintech businesses and financial institutions on AI and machine learning, and collaborations between banks and fintechs, such as the development of both core banking technology and innovative new solutions. Team headYvonne Dunnacts for fintech start-ups and established financial services companies. Travers Smith LLP’s cross-departmental team draws on strengths in technology, corporate, financial services and dispute resolution to advise a range of clients, such as start-ups, fintech giants and large financial institutions.

Site news – Announcements, updates, articles and press releases on Wikipedia and the Wikimedia Foundation. Detailed information on compliance and governance at Dermapharm can be found in our Dermapharm Code of Conduct as well as in the Dermapharm CSR Report 2020. In addition, we offer you the opportunity to join our IR news service in order to receive information from Dermapharm Holding SE promptly. From 1969 to 1974, Mr. Lanz studied business administration at the universities of Stuttgart and Berlin and graduated with a degree in business administration. Mr. Lanz began his professional career as an audit assistant for an auditor and tax consultant in Berlin. In 1977, Mr. Lanz joined Bayerische Hypotheken- und Wechselbank AG, where he served as branch manager from 1983 to 1990.

In 2007, Biocon and Abraxis BioScience, Inc. entered into an agreement which helped Biocon out-license the rights to develop and market a biosimilar version of GCSF (Granulocyte Colony-Stimulating Factor) to North American and European markets. Ltd. in 2003 as a joint venture with the Cuban institute CIMAB to develop and market a range of MAbs and cancer vaccines. Clinigene International Limited is a subsidiary on Syngene offering international pharmaceutical majors Phase I-IV clinical trials and studies for novel/generic molecules.

Advising Lanistar Limited, which has recently pre-launched the world’s first polymorphic payment card, on the financial services implications of its card product. Advised international venture capital firm yabeo on its investment in digital mortgage lender Molo as part of a £266m debt and equity funding. Advising the sellers of Prepaid Financial Services on the sale of PFS, a multi-award winning European provider of white label payments and banking-as-a-service technology, to Australian listed EML Payments Limited bittrex review . Advising Aon on a strategic collaboration with Goldman Sachs for the development of a novel investment management platform for Aon’s captive insurance clients globally. Provided critical regulatory advice throughout Archax’ authorisation process, including on complex issues arising from the application of MiFID II and the CSDR in the context of digital securities and distributed ledger technology. In 2009, Biocon signed a collaboration agreement with Viatris to develop and commercialize generic biologics.

Tier 2 Firms

In 2007, Dr. Kern took over the chairmanship of the management of these companies, which he still holds today. Since 2003, he has been President of the Federal Association of the German Ready-Mixed Concrete Industry . Since 2003 and was Chairman from 2008 to 2011 and Vice Chairman from 2011 to 2013 of Construction Products Europe .

Fieldfisher’s cross-practice team comprises of lawyers with expertise in areas such as finance, regulatory, IT and corporate. It advises large tech companies who wish to acquire or invest in fintechs, and financial firms who are investing in fintech solutions. The practice has particular expertise in platform regulation and risk management, receivables finance, corporate fundraising, payment services and open banking. Simon Briskman, who leads the practice, is experienced in advising banks and other financial institutions on technology and outsourcing. Working closely with its colleagues in the US, Paul Hastings LLP provides a cohesive transatlantic service to international corporates and smaller domestic companies in the fintech space.

The team’s work covers blockchain and cryptocurrency projects, payments and lending, data protection and cyber security, among various other areas. Also notable is that it handles a significant amount of government policy-related work and is at the forefront of legislative developments in the fintech arena. The practice handles blockchain, payment services and AI matters, and Burnie has significant experience in cryptocurrencies. Provided fintech advice to a US private equity-backed financial account aggregation technology platform service provider, on its European arrangements to allow financial transaction account aggregation with global financial institutions. The practice has considerable experience in corporate and financial deals in the fintech sector, and it also handles IT and data protection matters.

Firms To Watch: Fintech

In 1986, Dr. Kern completed his studies in business administration at the Ludwig Maximilian University in Munich. In 1989, he received his doctorate in economics from the University of Paderborn. Dr. Kern Eurobond began his professional career in 1986 as Managing Director of HBK-Handel und Beteiligungen Kern GmbH & Co. KG. From 1991 onwards, he was a member of the management of Kies und Beton Baden-Baden GmbH & Co.


Viatris and Biocon will share development, capital and other costs to bring products to market. Viatris will have exclusive commercialisation rights in USA, Canada, Japan, Australia, New Zealand, EU and European Free Trade Association countries through a profit sharing arrangement with Biocon. In 2009, Biocon and Amylin Pharmaceuticals of the United States entered into an agreement to develop, commercialise and manufacture a novel peptide therapeutic for the potential treatment of diabetes.

Advising Aspen on a wide range of IT procurement needs, including multimillion IT procurement and seven figure savings in software licence matters. Provided key support in helping Liberis grow both domestically and internationally. Provided multidisciplinary support to APS/Cashplus on its journey to fully authorised bank status. Advising Glory Global on the €200m acquisition of a global touch-screen payment kiosks manufacturer. Advised EQT Ventures in respect of a seed investment in Treecard Ltd, the payment card provider partnered with Ecosia to facilitate reforestation activities. Advising Mollie on a number of aspects of its expansion into the UK, including advising on passporting arrangements under European directives and advising on post-Brexit transitional arrangements and beyond.

The amalgamated entity also benefits from ancillary support from Deloitte’s non-legal disciplines, including consulting, software development, risk advisory and tax. It acts for start-ups and established fintech companies on open banking, cryptocurrencies and blockchain, electronic payments, AI and regulatory matters, among others. ‘Formidable advocate’ Chris Hillis ‘the go-to Gandalf in the intricate world of technology legal advice’. Hill is a thought leader on mobile payments and is well-supported by Jacob Ghanty, who focuses on financial services regulation. Gowling WLGassists clients with debt and equity investments in the fintech sector, and it also handles IP, commercial contracts, regulatory issues and platform structuring matters. The group in London is part of a larger international practice that acts for clients globally.

Methods of developing, characterising and scaling up of conjugated monoclonal antibody production are being currently studied. Biocon Limited is an Indian biopharmaceutical company that is based in Bangalore, India. The company manufactures generic active pharmaceutical ingredients that are sold in over 120 countries across the globe, including the developed markets of the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations.

Leave a Reply

Your email address will not be published.